3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Gynecologic
2
Genitourinary
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
71
Neoplasm Metastasis
11
Brain Neoplasms
7
Triple Negative Breast Neoplasms
5
Stomach Neoplasms
3
Neoplasms
3
HER2-positive Breast Cancer
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
2
Breast Cancer With Brain Metastasis
2
Advanced Breast Cancer
2
Unresectable Locally Recurrent Breast Cancer
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Meningeal Carcinomatosis
1
Inflammatory Breast Neoplasms
1
HER2-negative Breast Cancer
1
HER2-low Hormone Receptor Positive Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
HER2 Overexpression
1
Glioma
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
29
Gemcitabine
16
Cyclophosphamide
14
Nivolumab
12
Carboplatin
12
Capecitabine
11
Trastuzumab
9
Paclitaxel
9
Magnetic Resonance Spectroscopy
8
Irinotecan
8
Bevacizumab
8
Albumin-Bound Paclitaxel
8
130-nm albumin-bound paclitaxel
8
olaparib
7
fludarabine
7
Docetaxel
7
spartalizumab
6
aldesleukin
6
Drug Therapy
6
Cisplatin
6
durvalumab
5
atezolizumab
5
Standard of Care
5
Specimen Handling
5
Oxaliplatin
5
Biopsy
5
sargramostim
4
palbociclib
4
niraparib
4
enzalutamide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
trastuzumab deruxtecan
×
Breast
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled